Cited 6 times in
Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이병완 | - |
dc.date.accessioned | 2023-08-22T07:18:40Z | - |
dc.date.available | 2023-08-22T07:18:40Z | - |
dc.date.issued | 2017-12 | - |
dc.identifier.issn | 2233-6079 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/196115 | - |
dc.description.abstract | The glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017 for pharmacological therapy. Many randomized clinical trials and systematic reviews report that GLP-1RAs have considerable glucose-lowering effect and lead to weight reduction and low risk of hypoglycemia when used as a monotherapy or combination therapy. The cardiovascular safety of GLP-1RAs has been assessed in several randomized clinical trials and systematic reviews. The results of cardiovascular outcome trials of long-acting GLP-1RAs (liraglutide, semaglutide) demonstrated cardiovascular benefits in subjects with type 2 diabetes mellitus and a high risk of cardiovascular disease. The GLP-1RA may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Korean Diabetes Association | - |
dc.relation.isPartOf | DIABETES & METABOLISM JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Hyun Jin Kim | - |
dc.contributor.googleauthor | Seok O Park | - |
dc.contributor.googleauthor | Seung Hyun Ko | - |
dc.contributor.googleauthor | Sang Youl Rhee | - |
dc.contributor.googleauthor | Kyu Yeon Hur | - |
dc.contributor.googleauthor | Nan Hee Kim | - |
dc.contributor.googleauthor | Min Kyong Moon | - |
dc.contributor.googleauthor | Byung Wan Lee | - |
dc.contributor.googleauthor | Jin Hwa Kim | - |
dc.contributor.googleauthor | Kyung Mook Choi | - |
dc.contributor.googleauthor | Committee of Clinical Practice Guidelines of the Korean Diabetes Association | - |
dc.identifier.doi | 10.4093/dmj.2017.41.6.423 | - |
dc.contributor.localId | A02796 | - |
dc.relation.journalcode | J00720 | - |
dc.identifier.eissn | 2233-6087 | - |
dc.identifier.pmid | 29272081 | - |
dc.subject.keyword | Cardiovascular benefit | - |
dc.subject.keyword | Clinical practice guideline | - |
dc.subject.keyword | Combination therapy | - |
dc.subject.keyword | Glucagon-like peptide-1 receptor agonist | - |
dc.subject.keyword | Hypoglycemia | - |
dc.subject.keyword | Monotherapy | - |
dc.contributor.alternativeName | Lee, Byung Wan | - |
dc.contributor.affiliatedAuthor | 이병완 | - |
dc.citation.volume | 41 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 423 | - |
dc.citation.endPage | 429 | - |
dc.identifier.bibliographicCitation | DIABETES & METABOLISM JOURNAL, Vol.41(6) : 423-429, 2017-12 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.